NCT01598454View on ClinicalTrials.gov

Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

June 30, 2015

Conditions
NeuroblastomaEwing's SarcomaWilm's TumorRetinoblastomaGlioma
Interventions
DRUG

racotumomab

Dosage form: intradermal injection. Dosage: 0.15 mg; 0.25 mg; 0.4 mg. Frequency: 3 biweekly injections or 6 biweekly injections. Duration: 4 weeks or 10 weeks.

Trial Locations (1)

1245

Prof. Dr. J. P. Garrahan National Children's Hospital, Buenos Aires

Sponsors
All Listed Sponsors
collaborator

Ministerio de Ciencia e Innovación, Spain

OTHER_GOV

lead

Laboratorio Elea Phoenix S.A.

INDUSTRY